Table 1.

Characteristics of studies included in the meta analysis

Author	Year	BP Medication	Design	Exposure (mo)	Nomotensives included	Vintage (yrs)	Age	N	BP baseline	BP final	LV mass index (g/m2)	Deaths	CV Events	Comments
Zannad	2006	Fosinopril	DBRCT	24	Yes	5.3	67	196	146/77	139/76	179	52	67	LVH required for randomization.
		Placebo				4.4	67	201	145/77	143/74	169	49	60
Takahashi	2006	Candesartan	PROBE	36 (stopped early)	Yes	2.74	60	43	153/82	149/80	143.3	0	7	Excluded pts with CVD
		Nothing		19.4 avg exposure		2.77	62	37	152/85	153/83	152.4	7	17	Primary prevention trial
Suzuki	2008	ARBs	Randomized open	36	No	3.7	59	180	154/81	140/80		25	34	Treatment and outcomes not masked
		Nothing				3.7	60	180	156/82	140/78		38	59
Cice	2003	Carvedilol	DBRCT for 12 mo, then open label	24	Yes	7.1	55	58	134/75	120/70		30	17	Dilated cardiomyopathy required
		Placebo				6.8	55	56	135/75	135/76		41	39	All pts on ACE inhibitors or ARBs
Tepel	2008	Amlodipine	DBRCT	19	No	2.3	60	123	140/80	130/unchanged		15	19
		Placebo				1.9	62	128	141/80	140/unchanged		22	32

DBRCT: double-blind randomized controlled trial. PROBE: Prospective randomized open-label blinded end-point, CV cardiovascular, CVD cardiovascular disease, LVH left ventricular hypertrophy, MAP Mean arterial pressure. ARBs angiotensin receptor blockers. NA not available.